2 Amendments of Ivan JAKOVČIĆ related to 2016/2057(INI)
Amendment 44 #
Draft opinion
Paragraph 3
Paragraph 3
3. Supports competition in generic medicines, which allows broadetter access to medicines in LMICs; calls, in particular, for the EU and the Member States to support actively governments that use the available legal measures, including TRIPS safeguards and flexibilities, to protect and promote public health; calls also for the EU to immediately stop targeting countries such as India that have implemented progressive TRIPS- compliant IP policies which promote access to medicines, through its watch-list of ‘priority countries’;
Amendment 56 #
Draft opinion
Paragraph 4
Paragraph 4
4. Stresses that, without information based on transparency oft research and development costs to originator companies and information on the actual prices paid for medicines across the EU, any discussion or conclusions on fair medicine prices remains impossible; recalls the Commission’s commitment to greater transparency of EU positions, specific legal proposals, and negotiating texts in the TTIP negotiations;